![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Preprint)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
2MB |
Preview |
PDF (Supplementary Material)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
4MB |
| Item Type: | Preprint |
|---|---|
| Title: | Disruption of basal CXCR4 oligomers impairs oncogenic properties in lymphoid neoplasms |
| Creators Name: | Mobach, S, Bergkamp, N.D., Ma, Z, Haselager, M.V., Anbuhl, S.M., Jurriens, D, van den Bor, J., Wang, Z., Crudden, C., Roos, J.L., Perez Almeria, C.V., Boergonje, R.A., Lohse, M.J., Bosma, R., Eldering, E., Siderius, M., Wu, W., Spaargaren, M., Tonino, S.H., Kater, A.P., Smit, M.J. and Heukers, R. |
| Abstract: | The chemokine receptor CXCR4 is overexpressed in many cancers and contributes to pathogenesis, disease progression, and resistance to therapies. CXCR4 is known to form oligomers, but the potential functional relevance in malignancies remain elusive. Using a newly established nanobody-based BRET method, we demonstrate that oligomerization of endogenous CXCR4 on lymphoid cancer cell lines correlates with enhanced expression levels. Specific disruption of CXCR4 oligomers reduced basal cell migration and pro-survival signaling via changes in the phosphoproteome, indicating the existence of basal CXCR4-oligomer-mediated signaling. Oligomer disruption also inhibited growth of primary CLL 3D spheroids and sensitized primary malignant cells to clinically used Bcl-2 inhibitor venetoclax. Given its limited efficacy in some patients and the ability to develop resistance, sensitizing malignant B-cells to venetoclax is of clinical relevance. Taken together, we established a new, non-canonical and critical role for CXCR4 oligomers in lymphoid neoplasms and demonstrated that selective targeting thereof has clinical potential. SIGNIFICANCE STATEMENT: Class A GPCRs, including the chemokine receptor CXCR4, can form oligomers, but their functional relevance remains poorly understood. This study provides evidence for the role of basal CXCR4 oligomers in lymphoid neoplasms, where they drive pro-survival signaling, migration, and tumor growth. We use a novel nanobody-based BRET method to demonstrate that endogenous CXCR4 constitutively oligomerizes in lymphoid cancer cells, correlating with receptor expression levels. Pharmacological disruption of these oligomers reduces tumorassociated signaling, impairs spheroid growth, and sensitizes patient-derived malignant cells to the apoptosis-inducing drug Venetoclax. Since CXCR4 is frequently overexpressed and potentially clustered in various malignancies, this work offers broader implications for enhancing treatment efficacy, overcoming drug resistance, and potentially reducing side effects across multiple cancer types. |
| Keywords: | Leukemia, CXCR4, Receptor Oligomerization, Drug Sensitization |
| Source: | bioRxiv |
| Publisher: | Cold Spring Harbor Laboratory Press |
| Article Number: | 2024.12.06.627249 |
| Date: | 7 December 2024 |
| Official Publication: | https://doi.org/10.1101/2024.12.06.627249 |
Repository Staff Only: item control page
